Moyamoya Disease and the Risk of Parkinson's Disease
Annals of Clinical and Translational Neurology · 2025
DOI: 10.1002/acn3.70191 ↗Kurz gefasst
Fallbericht in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Dallah Yoo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Moyamoya Disease, Parkinson Disease, Ubiquitin-Protein Ligases, Adenosine Triphosphatases. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation of Korea (NRF), Korea Government (MSIT), Bio & Medical Technology Development Program.
Abstract (Originalsprache)
Objectives
Moyamoya disease (MMD) is a rare cerebrovascular disorder characterized by the progressive narrowing of arteries at the base of the brain, forming abnormal collateral vascular networks. While vascular parkinsonism is noted in MMD, its link to Parkinson's disease (PD) has not been explored. We aimed to determine whether the risk of PD is increased in patients with MMD and to identify the potential role of the RNF213 gene.
Methods
We report two cases of PD with a history of MMD associated with the Arg4810Lys variant of RNF213 . Using the Korean National Health Insurance Service database, we studied the association between MMD and subsequent PD risk using Cox proportional hazards regression analysis. Moreover, we explored the interaction between α‐synuclein and RNF213 proteins by overexpressing SNCA and RNF213 in SH‐SY5Y cells. Furthermore, we confirmed the proximity of Lewy pathology and RNF213 proteins in postmortem brain tissues from three patients with PD and age‐matched controls.
Results
Among 16,830 patients aged ≥ 40 with MMD, 3415 were enrolled, excluding those with prior PD or stroke, along with a matched control group of 33,974. The analysis revealed an increased PD risk in patients with MMD (hazard ratio = 4.45 [3.40–5.82], p < 0.0001). Overexpression of RNF213 resulted in cytoplasmic inclusions, which were worsened by the co‐expression of SNCA and the Arg4810Lys variant of RNF213. Histological studies confirmed the co‐localization of α‐synuclein aggregates and RNF213 proteins in PD brain tissues.
Interpretation
This study confirms the heightened PD risk in patients with MMD and suggests a pathophysiological link through α‐synuclein and RNF213 interactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, Republic of Korea.
- Department of Pharmacology, Sungkyunkwan University School of Medicine, Samsung Biomedical Research Institute (SBRI), Suwon, Republic of Korea.
- Department of Preventive Medicine, Kyung Hee University College of Medicine, Seoul, Republic of Korea.
- Department of Pathology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
ORCID-Profile: Dallah Yoo
Förderung
- National Research Foundation of Korea (NRF)
- Korea Government (MSIT)
- Bio & Medical Technology Development Program
- Ministry of Science and ICT, South Korea
Zitieren
APA
Yoo, D., Shin, J. Y., Lee, R., Cheon, J., Kim, J. H., Kim, D., Won, J. K., Oh, I. H., Lee, Y., & Ahn, T. B. (2025). Moyamoya Disease and the Risk of Parkinson's Disease. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70191
Vancouver
Yoo D, Shin JY, Lee R, Cheon J, Kim JH, Kim D, et al. Moyamoya Disease and the Risk of Parkinson's Disease. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70191
BibTeX
@article{Yoo2025,
author = {Yoo, Dallah and Shin, Jeong-Yong and Lee, Rugyeom and Cheon, Jiwon and Kim, Ji Hun and Kim, Doeun and Won, Jae-Kyung and Oh, In-Hwan and Lee, Yunjong and Ahn, Tae-Beom},
title = {Moyamoya Disease and the Risk of Parkinson's Disease},
journal = {Annals of Clinical and Translational Neurology},
year = {2025},
doi = {10.1002/acn3.70191}
}
EUVIMED